Bepaling van creatinine bij therapie met platinumderivaten enkel noodzakelijk elke drie weken

Translated title of the contribution: Creatinine determination in platinum-based therapy only mandatory every three weeks

S. van der Gaag*, M. Labots, E. L. Swart, M. Crul

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional


Background Platinum-based chemotherapy is a well-known therapeutic option for multiple types of cancer and also known for its nephrotoxicity. Currently, renal function should be assessed at each course of platinum-based chemotherapy, but there is no national guideline regarding frequency of renal function determination. Objective The primary objective was to determine the frequency of clinically relevant dosage adjustments of cisplatin and carboplatin in patients with an interval of ≤ 7 versus > 7 days between renal function assessment and administration of cisplatin or carboplatin. Methods We conducted a multicenter retrospective database research in two academic medical centers. A query was built to extract data from the electronic health record. Results In total, 512 patients receiving cisplatin and 628 receiving carboplatin were included. Median time to clinically relevant change in renal function occurred in 67 days for cisplatin and 64 days for carboplatin. For cisplatin, gender, age, indication and baseline renal function were significant factors influencing changes in renal function. For carboplatin these factors were age and renal baseline function. Conclusion Creatinine determination in carboplatin and cisplatin therapy is only mandatory every three weeks to detect a clinically relevant decrease in renal function in time.
Translated title of the contributionCreatinine determination in platinum-based therapy only mandatory every three weeks
Original languageDutch
Pages (from-to)23-28
Number of pages6
JournalPharmaceutisch Weekblad
Issue number6
Publication statusPublished - 11 Feb 2022

Cite this